Cardiology最新文献

{"title":"Utilization of Guideline-Directed Medical Therapies and Transcatheter-Edge-to-Edge Repair in Patients with Significant Secondary Mitral Regurgitation.","authors":"Varun Bhasin, Azin Vakilpour, Krishna Ravindra, Daniel Koropeckyj-Cox, Srinivas Denduluri, Paul Fiorilli, Aditya Parikh, Ray Hu, Marielle Scherrer-Crosbie","doi":"10.1159/000551963","DOIUrl":"https://doi.org/10.1159/000551963","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with heart failure with reduced ejection fraction and significant secondary mitral regurgitation (MR) benefit from optimal guideline-directed medical therapies (GDMTs). In those who remain symptomatic despite optimal GDMT, transcatheter edge-to-edge repair (TEER) has been shown to reduce rates of heart failure hospitalization and all-cause mortality. The objective of this study was to evaluate the utilization of GDMT and TEER in patients with significant secondary MR and reduced left ventricular ejection fraction (LVEF) and determine gaps in care delivery.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of all patients in a tertiary care center who had newly diagnosed moderate to severe or severe secondary MR and a LVEF of <50% on echocardiography. Use of medical therapy was evaluated at 3 months after the initial echocardiogram in surviving patients. Optimal GDMT was defined as treatment with 3 or more heart failure therapies. Both univariable and multivariable logistic regression analyses were conducted after excluding patients who experienced early mortality within 3 months.</p><p><strong>Results: </strong>508 patients were identified from a retrospective chart query. 101 patients (20%) died (median time to death of 56 days) with 63 of these patients experiencing early mortality within 90 days. The remaining 445 patients (age 68 ± 15 years, 55% male, LVEF 29 ± 11%) were analyzed, including 324 with moderate to severe MR and 121 with severe MR. 237 patients (53%) were on optimal GDMT at 3 months after the initial echo. Older patients (OR 0.97, 95% CI 0.95-0.99), patients with coronary artery disease (OR 0.66, 95% CI 0.45-0.96, p = 0.03), cancer (OR 0.55, 95% CI 0.35-0.85, p = 0.01), and chronic kidney disease (CKD) (OR 0.60, 95% CI 0.41-0.87, p = 0.01) were less likely to be on optimal GDMT at 3 months. Age and CKD remained significant variables in the multi-variable analysis. Nine patients (1.8%) underwent TEER with a median time to TEER of 140 days.</p><p><strong>Conclusion: </strong>Patients with significant secondary MR and reduced LVEF have a high mortality. Implementation of optimal GDMT was imperfect, and TEER was rarely utilized. Older patients and those with CKD were less likely to be on optimal GDMT at 3 months. Further study is needed to understand gaps in GDMT implementation and the effective utilization of TEER.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coffee Consumption and Atrial Fibrillation: An In-Depth Interpretation behind the Evidence.","authors":"Weina Ren, Huijun Zheng, Hao Liu","doi":"10.1159/000553110","DOIUrl":"10.1159/000553110","url":null,"abstract":"","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-2"},"PeriodicalIF":1.9,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review Certainty of Evidence and Procedural Durability of Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: An Umbrella Review of Meta-Analyses.","authors":"Arthur Cordeiro Simão, Marcos Benito Gonçalves de Oliveira, Antônio da Silva Menezes Junior","doi":"10.1159/000552974","DOIUrl":"10.1159/000552974","url":null,"abstract":"<p><strong>Introduction: </strong>This umbrella review aimed to evaluate the certainty and consistency of the available evidence rather than to provide a new procedural comparison. We synthesized systematic reviews comparing surgical septal myectomy (SM) versus alcohol septal ablation (ASA) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to critically assess the certainty of findings.</p><p><strong>Methods: </strong>An umbrella review of meta-analyses was conducted following Cochrane and PRISMA guidelines. A systematic search of four databases was performed. Methodological quality, risk of bias, and study overlap were assessed. Quantitative synthesis was performed using a random-effects model, and the certainty of evidence was classified using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.</p><p><strong>Results: </strong>Six meta-analyses comprising 31 unique primary studies and 12,860 patients were included, demonstrating very high study overlap. ASA was associated with a significantly higher risk of reoperation compared to SM, supported by high-certainty evidence. Conversely, for all other outcomes, including mortality and permanent pacemaker implantation, the certainty of evidence was consistently classified as very low due to inconsistency and imprecision.</p><p><strong>Conclusion: </strong>High-certainty evidence supports SM as the more durable intervention for oHCM, demonstrated by a reduced need for reoperations. Notably, the evidence for mortality outcomes is of very low certainty, precluding definitive conclusions regarding clinical equivalence or technique superiority. This review identifies current knowledge gaps regarding survival benefits to inform clinical practice and future research.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2026-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the Link between Inflammatory Biomarkers and Coronary Artery Ectasia Severity: A Systematic Review and Meta-Analysis.","authors":"Hang Zhang, Xin Chen","doi":"10.1159/000552688","DOIUrl":"10.1159/000552688","url":null,"abstract":"<p><strong>Introduction: </strong>Coronary artery ectasia (CAE), with increasing detection, and the role of inflammation remain controversial. This meta-analysis explored correlations between multiple inflammatory markers and the occurrence and severity of CAE.</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane Library, and Web of Science were searched from inception to July 2025 for relevant studies. Literature screening, data extraction, and quality assessment were performed. Meta-analysis was conducted using Review Manager 5.3, with fixed- or random-effects models based on heterogeneity; mean difference (MD), odds ratio (OR), bias risk, and sensitivity analyses were computed.</p><p><strong>Results: </strong>Fifty-three studies involving 9,168 subjects were included. Compared with the control group, patients with CAE had higher levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). The ratio of white blood cells (WBCs) to neutrophils in CAE patients was higher than that in coronary artery disease (CAD) and non-coronary artery (NCA) populations. Lymphocytes showed a gradient distribution of \"NCA > CAE > CAD\". The level of monocytes in CAE patients was higher than that in CAD patients, but similar to that in NCA patients. There was no significant correlation between the neutrophil-to-lymphocyte ratio levels of CAE patients and those of CAD patients. The levels of hs-CRP and lymphocytes in CAE patients were positively correlated with the severity of CAE. Multivariate analysis showed that hs-CRP (OR = 1.78) and WBC (OR = 1.00) were the factors related to CAE.</p><p><strong>Conclusion: </strong>Hs-CRP, IL-6, TNF-α, and various inflammatory cells are related to the occurrence of CAE. Hs-CRP and lymphocytes can indicate the severity of CAE.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-21"},"PeriodicalIF":1.9,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13436928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148238847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Safety Profile of Ticagrelor among Older Adults (Age ≥75 years): A Pharmacovigilance Analysis.","authors":"Inbar Yacoby-Halevi, Boris Kruchin, Chen Gadot, Dmitri Guz, Assaf Rotmensh, Yonatan Shaleve, Hila Sharon, Noam Greenberg, Boris Fishman, Edward Itelman, Aviad Rotholz, Keren Skalsky, Katia Orvin, Alon Eisen, Ran Kornowski, Tsahi T Lerman, Amos Levi","doi":"10.1159/000552641","DOIUrl":"10.1159/000552641","url":null,"abstract":"<p><strong>Introduction: </strong>Ticagrelor is a widely used potent P2Y12 inhibitor in patients aged ≥75 years with acute coronary syndromes. Despite its widespread use, data on ticagrelor's safety in older adults remain limited.</p><p><strong>Methods: </strong>We performed a retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System from 2010 to 2024. Disproportionality analysis compared ticagrelor with clopidogrel, assessing predefined adverse events in adults (<75 years) and older adults (≥75 years). For each group, reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated, and differences between age groups were evaluated using interaction analysis.</p><p><strong>Results: </strong>A total of 6,476 ticagrelor-related adverse event reports were included: 4,795 (74%) adults and 1,681 (26%) older adults. In older adults, ticagrelor was not associated with increased reporting of dyspnea, intracranial hemorrhage, complete atrioventricular block, or gout. Acute kidney injury (AKI) was the only event reported more frequently in older adults (ROR 2.3 [95% CI: 1.5-3.6] vs. 0.6 [95% CI: 0.4-0.9]; p < 0.001). Ticagrelor was associated with lower reporting of gastrointestinal bleeding, hematuria, hemoptysis, and anemia in both age subgroups. Bradycardia and syncope were reported more frequently among adults (p = 0.002 and p < 0.001, respectively).</p><p><strong>Conclusion: </strong>Ticagrelor appears generally safe in older adults (≥75 years), with no excess reporting of major adverse events compared to younger adults, aside from a higher reporting of AKI.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13423310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter versus Surgical Aortic Valve Replacement in Patients Aged 50-65 Years: A Propensity Score-Matched 5-Year Study.","authors":"Mohamed Doma, Mahmoud Ismayl, Adham Ramadan, Ibrahim Kamel, Pedro A Villablanca, Ashequl M Islam, Andrew M Goldsweig","doi":"10.1159/000552949","DOIUrl":"10.1159/000552949","url":null,"abstract":"<p><strong>Introduction: </strong>Comparative long-term outcomes of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in younger patients remain incompletely defined, particularly beyond early follow-up. This study evaluated short-, mid-, and long-term outcomes between TAVR and SAVR in patients aged 50-65 years using a multicenter retrospective cohort.</p><p><strong>Methods: </strong>Patients with aortic stenosis aged 50-65 years undergoing TAVR or SAVR were identified using the TriNetX database. Patients were matched 1:1 using propensity score matching (PSM). Outcomes were assessed at 30 days, 1 year, and 5 years. The primary endpoint was a composite of all-cause mortality or stroke; secondary endpoints included hospitalization, major bleeding, acute kidney injury (AKI), cardiogenic shock, and valve dysfunction. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to estimate the overall effect size.</p><p><strong>Results: </strong>PSM yielded 1,041 well-balanced pairs. At 30 days, TAVR was associated with a lower risk of the primary composite endpoint (3.0% vs. 5.6%; HR 0.53; 95% CI: 0.34-0.82; p = 0.004), all-cause mortality (HR 0.50; p = 0.03), major bleeding (HR 0.29; p < 0.001), AKI (HR 0.39; p < 0.001), and cardiogenic shock (HR 0.28; p < 0.001). At 1 year, the composite endpoint, mortality, and stroke did not differ significantly between groups; major bleeding remained lower with TAVR (HR 0.50; p < 0.001). At 5 years, TAVR was associated with higher risks of the primary composite endpoint (18.6% vs. 15.5%; HR 1.27; 95% CI: 1.03-1.57; p = 0.02) and all-cause mortality (13.7% vs. 8.3%; HR 1.81; 95% CI: 1.39-2.37; p < 0.001), while major bleeding remained lower (HR 0.65; p < 0.001).</p><p><strong>Conclusion: </strong>TAVR demonstrated early safety but a higher long-term risk of mortality and composite adverse outcomes at 5 years compared with SAVR.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Promise of Cilostazol in Refractory Vasospastic Angina: The Need for Multicentre Collaboration.","authors":"Adnan Duha Cömert, Ercan Taştan","doi":"10.1159/000552955","DOIUrl":"10.1159/000552955","url":null,"abstract":"","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-2"},"PeriodicalIF":1.9,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of N-Terminal Pro-Brain Natriuretic Peptide Combined with High-Sensitivity Troponin-I for Progression to High-Risk Status in Acute Pulmonary Embolism.","authors":"Yangyi Lin, Xinyun Wang, Xiongying Lin, Tongqing Yao, Xian Jin","doi":"10.1159/000552873","DOIUrl":"10.1159/000552873","url":null,"abstract":"<p><strong>Introduction: </strong>Despite significant advances in the diagnosis and treatment of acute pulmonary embolism (APE), mortality remains high among high-risk APE patients. Timely identification of APE patients at risk of progression to high-risk status may enable intensified monitoring and timely treatment escalation, thereby potentially improving prognosis. The current guideline stratification system has a limited ability to distinguish patients likely to progress to high-risk status. This study aimed to evaluate the predictive value of combined N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin-I (hs-cTnI) for clinical deterioration to high-risk states in APE patients.</p><p><strong>Methods: </strong>A retrospective study included patients with APE who were diagnosed by computed tomography pulmonary angiography from January 2022 to July 2024. Patients were classified according to the presence or absence of progression to high-risk status.</p><p><strong>Results: </strong>A total of 569 patients were enrolled, of whom 23 progressed to high-risk status and 546 did not. Both NT-proBNP and hs-cTnI were significant predictors of progression to high-risk status: NT-proBNP (odds ratio [OR]: 1.019, 95% confidence interval [CI]: 1.007-1.032, p = 0.002) and hs-cTnI (OR: 7.241, 95% CI: 2.916-17.983, p < 0.001). The area under the receiver operating characteristic curve for the NT-proBNP and hs-cTnI combination in predicting progression to high-risk status was 0.852. Patients with elevated levels of both NT-proBNP (≥1,860 pg/mL) and hs-cTnI (≥0.03 ng/mL) had a significantly higher rate of progression to high-risk status (25.9%), especially among intermediate-high-risk patients (31.7%).</p><p><strong>Conclusions: </strong>The combination of NT-proBNP and hs-cTnI provides clinically useful prediction of impending deterioration to high-risk status in APE, particularly among intermediate-high-risk patients.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C-Reactive Protein and Long-Term Risk of Death in Patients with Myocardial Infarction.","authors":"Julie Borchsenius, Kristian H Kragholm, Deepak L Bhatt, Martin Bødtker Mortensen, Alexander Egeberg, Carlo Alberto Barcella, Christoffer Polcwiartek, Maria Dons, Ditte Vesterlev, Adam Femerling Langhoff, Caroline Espersen, Majid Afzal, Johanna Frary, Christina Byrne, Monija Mrgan, Roxana Mihaela Popescu, Arman Qamar, Michael Hecht Olsen, Lars Valeur Køber, Christian Torp-Pedersen, Gunnar Gislason, Muthiah Vaduganathan, Brittany Weber, Tor Biering-Sørensen, Manan Pareek","doi":"10.1159/000551869","DOIUrl":"10.1159/000551869","url":null,"abstract":"<p><strong>Introduction: </strong>The long-term prognostic value of standard C-reactive protein (CRP) in patients with myocardial infarction is unknown.</p><p><strong>Methods: </strong>Using Danish nationwide registries, we identified patients with a diagnosis of myocardial infarction from 2013 through 2020, who had a CRP measurement ≤24 h of index hospitalization. The primary outcome was death from any cause, and the secondary outcome was hospitalization or outpatient contact for new-onset heart failure. Absolute and relative risks for outcomes according to CRP quartiles at days 0-30 and 31-365 were calculated using multivariable Cox regression with average treatment effect modeling, adjusted for demographics and clinical features, including high-sensitivity troponin concentrations.</p><p><strong>Results: </strong>A total of 29,035 patients with myocardial infarction were included. Median CRP was 4 mg/L, and quartile intervals were quartile 1: <2.9 mg/L, quartile 2: 2.9 to <4 mg/L, quartile 3: 4 to <12 mg/L, and quartile 4: ≥12 mg/L. At 0-30 days, 1,660 patients had died, and 1,861 died between days 31 and 365. The standardized absolute risk of death at both 0-30 and 31-365 days was lowest among patients in quartile 1 (0-30 days: 2.8%, 31-365 days: 4.1%) and highest among patients in quartile 4 (0-30 days: 9.7%, 31-365 days: 9.5%). The standardized relative risks of death increased in a stepwise fashion from quartile 2 to quartile 4 when using quartile 1 as the comparator. Similar findings were observed for heart failure.</p><p><strong>Conclusion: </strong>Among patients with myocardial infarction, higher CRP concentrations were significantly associated with a higher risk of death and incident heart failure.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Double-Effect Kissing Balloon Technique in Left Main Bifurcation Percutaneous Coronary Intervention: Design and Rationale of Japanese Coronary Intervention Using Drug-Eluting and Perfusion Therapy for Left Main Disease Registry.","authors":"Takayuki Warisawa, Shuhei Odagiri, Masanobu Ishii, Toshiyuki Nagai, Taku Asano, Yohei Sotomi, Mamoru Nanasato, Kazuya Kawai, Hitoshi Matsuo, Shigeru Saito","doi":"10.1159/000552600","DOIUrl":"10.1159/000552600","url":null,"abstract":"<p><strong>Introduction: </strong>The Japanese Coronary Intervention Using Drug-Eluting and Perfusion Therapy for Left Main Disease Registry (JDEPTH-LM Registry) is a prospective, multicenter observational study in 32 Japanese institutions evaluating the double-effect kissing balloon technique (W-KBT) as a novel strategy for left main trunk percutaneous coronary intervention (LM-PCI). This approach combines provisional crossover stenting, proximal optimization technique, KBT, and prolonged (≥30 s) KBT using a perfusion balloon for the left anterior descending artery and a drug-coated balloon for the left circumflex (LCx) ostium.</p><p><strong>Methods: </strong>A total of 280 patients with stable/unstable angina or non-ST-elevation myocardial infarction and LCx ostial involvement will be enrolled. The co-primary endpoints are procedural success and major adverse cardiovascular events at 12 months. The JDEPTH-LM Registry will provide clinical data on the safety and efficacy of W-KBT, which may enhance outcomes in LM-PCI involving the LCx ostial lesion.</p><p><strong>Conclusion: </strong>These findings could contribute to the optimization of complex LM-PCI strategies in clinical practice.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.9,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13354280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}